In addition, it has been reported that SMAD4 mutation can be used to identify the NSCLC patients with poor survival, and SMAD4 may be a therapeutic target in NSCLC.[15] These driver mutations would include ras, EGF receptor, p53, etc.[34] In our study, we just analysis the expression of SMAD4 in NSCLC by IHC, and the genes mutations present in the NSCLC tumor samples were not included. This evidence concerns the gene TP53 and non-small cell lung carcinoma.